The Effect of Distal Versus Proximal iPACK on Pain After Total Knee Arthroplasty

NCT ID: NCT07080892

Last Updated: 2025-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-12

Study Completion Date

2027-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Total knee arthroplasty (TKA) often results in significant postoperative pain, which can hinder recovery despite advances in surgical and anesthetic techniques. Traditional pain management methods like femoral nerve blocks may impair motor function, delaying rehabilitation. The iPACK block, targeting the posterior knee without affecting motor control, offers a promising alternative. This study aims to compare the effectiveness of two iPACK block approaches-proximal (at the distal femoral shaft) and distal (between the femoral condyles)-in managing postoperative pain in TKA patients. In a double-blind, randomized controlled trial with 120 participants, pain scores, opioid use, and time to rescue analgesia will be assessed. The hypothesis is that the distal iPACK block provides superior pain relief, potentially improving patient outcomes and recovery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Total knee arthroplasty (TKA) is one of the most frequently performed orthopedic procedures in modern medicine. Despite advancements in surgical techniques and perioperative care, postoperative pain management remains a significant challenge and a key factor influencing time to mobilization, patient satisfaction, and length of hospital stay. Commonly used analgesic techniques, such as femoral nerve blocks or epidural analgesia, while effective, can impair motor function and thus delay rehabilitation.

To minimize motor deficits while still providing effective pain relief, newer regional anesthesia techniques have been introduced into clinical practice. One such technique is the iPACK block (interspace between the popliteal artery and posterior capsule of the knee), which targets the posterior knee - an area often insufficiently covered by conventional nerve blocks. This method involves administering a local anesthetic into the space between the popliteal artery and the posterior capsule of the knee joint, offering analgesia without significant motor impairment.

Originally, the iPACK block was described as being performed at the level of the distal femoral shaft, several centimeters above the femoral condyles. Recently, however, a more distal variation of the technique has emerged, where the anesthetic is injected directly between the femoral condyles. This may provide more effective coverage of the posterior knee capsule's innervation. To date, there are no randomized trials that directly compare the efficacy of the distal and proximal iPACK approaches in terms of postoperative pain as the primary outcome.

Our aim is to conduct a prospective, randomized, placebo-controlled, double-blind clinical trial to compare the effectiveness of the distal and proximal iPACK blocks in patients undergoing TKA. A total of 120 patients will be enrolled and randomly assigned to one of two groups.

* In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).
* In the distal iPACK group, the same volume and concentration of anesthetic will be injected at the most distal part of the thigh, between the femoral condyles.

All participants, regardless of group assignment, will also receive an adductor canal block with 20 ml of 0.25% levobupivacaine without adrenaline. In addition, all patients will receive standard analgesic therapy consisting of paracetamol (1 g IV every 8 hours) and diclofenac (75 mg IV every 12 hours). If necessary, rescue opioid doses will be available according to individual needs.

The efficacy of each approach will be assessed using several parameters: pain intensity will be measured using the Visual Analogue Scale (VAS) both at rest and during active knee movement (up to 45 degrees) at 6, 12, and 24 hours postoperatively. Secondary outcomes include total opioid consumption within 24 hours and time to first opioid rescue dose.

The hypothesis of our study is that the distal iPACK approach will provide more effective postoperative pain control compared to the original proximal technique. If confirmed, the findings could influence perioperative pain management protocols for TKA, support the broader adoption of the distal iPACK block in clinical practice, enhance patient comfort, reduce opioid use, promote earlier mobilization, and potentially shorten hospital stays.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain Following Knee Arthroplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

proximal iPACK group

In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).

Group Type EXPERIMENTAL

proximal iPACK

Intervention Type PROCEDURE

● In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).

distal iPACK group

In the distal iPACK group, the participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the most distal part of the thigh, between the femoral condyles.

Group Type EXPERIMENTAL

distal iPACK

Intervention Type PROCEDURE

● In the distal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the most distal part of the thigh, between the femoral condyles.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

distal iPACK

● In the distal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the most distal part of the thigh, between the femoral condyles.

Intervention Type PROCEDURE

proximal iPACK

● In the proximal iPACK group, participants will receive 20 ml of 0.25% levobupivacaine with adrenaline (1:200,000), injected at the level of the distal femoral shaft (a straight portion of the femur without the condyles).

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 and 80 years
* Patients undergoing primary unilateral total knee arthroplasty (TKA) for osteoarthritis
* Ability to understand and sign informed consent
* American Society of Anesthesiologists (ASA) classification I-III
* Ability to cooperate and participate in postoperative pain assessments (e.g., VAS)

Exclusion Criteria

* Refusal to participate or failure to sign informed consent
* Bilateral or revision TKA
* Partial or unicondylar knee replacement
* Severe knee deformity (flexion, varus, or valgus \>30°)
* Diagnosis other than osteoarthritis (e.g., rheumatoid arthritis, septic arthritis, post-traumatic arthritis)
* Allergy to local anesthetics or any medications used in the study
* Contraindications to regional anesthesia (e.g., infection at the injection site, coagulopathy, therapeutic anticoagulation)
* BMI \> 40 kg/m²
* Severe renal impairment (KDIGO stage G4 or higher) or liver failure (Child-Pugh score ≥ 10)
* Prior surgery or vascular procedure on the femoral vessels of the operated limb
* Language barrier or inability to assess pain using the VAS
* Planned outpatient (same-day discharge) procedure
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Comenius University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1st Department of Anaesthesiology and Intensive Care Medicine

Bratislava, , Slovakia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Slovakia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Andrej Dano, MD

Role: CONTACT

+421911571616

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Andrej Dano, MD

Role: primary

+421911571616

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UNB/RU/052025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

IPACK Block in Total Knee Arthroplasty
NCT03692858 UNKNOWN PHASE2